BLA 018781 · Lilly
Humulin N
Insulin Susp Isophane Recombinant Human · Injection · Insulin
Last checked: Nov 20, 2026Latest source record: Jun 27, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1982
Oct 28, 1982
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Susp Isophane Recombinant Human" as an intervention, any sponsor and status, largest first.
Biocon LimitedIndustry
NCT04022304 · 90 participants · Start Jun 15, 2019 · Primary completion Dec 21, 2019
Drug: Biocon Insulin N; Humulin® N · For: Healthy Volunteer
Sites: Neuss, Germany
Biocon LimitedIndustry
NCT04022291 · 78 participants · Start Jun 15, 2019 · Primary completion Jan 20, 2020
Drug: Humulin ®70/30; Biocon Insulin 70/30 · For: Healthy Volunteer
Sites: Mainz, Germany; Neuss, Germany
WockhardtIndustry
NCT01358435 · 53 participants · Start Jan 2011 · Primary completion May 2011
Drug: 30% Regular Insulin Human Neutral and 70%Isophane Insulin; Novolin 70/30 · For: Diabetes Mellitus
Sites: Chula Vista, California
GeropharmIndustry
NCT04501250 · 52 participants · Start Oct 23, 2017 · Primary completion Jan 1, 2018
Drug: Rinsulin NPH; Humulin NPH · For: Pharmacokinetics; Bioequivalence
Sites: Yaroslavl, Russia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Humulin N (Insulin NPh Human Isophane)
2024 spending
$40.0M
Beneficiaries
79,060
286,710 claims
Per beneficiary
$506
$3.79 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $126,145,792 |
| 2021 | $116,672,726 |
| 2022 | $104,432,622 |
| 2023 | $94,070,976 |
| 2024 | $40,008,424 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study.
Andersen G, Singh G, Murugesan SMN, et al. · Diabetes Obes Metab 2023 · Randomized Controlled Trial, Clinical Trial, Phase I
- Long-acting insulins alter milk composition and metabolism of lactating dairy cows.
Winkelman LA, Overton TR · J Dairy Sci 2013 · Randomized Controlled Trial
- Lispro insulin as premeal therapy in type 1 diabetes: comparison with Humulin R.
Daniels AR, Bruce R, McGregor L · N Z Med J 1997 · Clinical Trial, Comparative Study
- Safety and efficacy of insulin lispro in patients with diabetes mellitus.
Che£a D, Strgchinariu R, Trifan E, et al. · Rom J Intern Med 1998 · Clinical Trial
- Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus.
Rassi N, Moraes SM, Alves AG, et al. · Arch Endocrinol Metab 2016 · Comparative Study, Randomized Controlled Trial
- An investigation of the action of Neutral Protamine Hagedorn human analogue insulin in dogs with naturally occurring diabetes mellitus.
Palm CA, Boston RC, Refsal KR, et al. · J Vet Intern Med 2009 · Clinical Trial, Research Support, Non-U.S. Gov't
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.